Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Protein Therapies
Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy
November 22nd, 2007
Pieris AG, a biopharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced the appointment of Dr Angelika Stern as Chief Operating Officer to the Company. Pieris has also announced the promotion with immediate effect of Dr Andreas Hohlbaum from the position of Director of Science and Preclinical Development to Chief Technology Officer. The appointment of Dr Angelika Stern at Pieris coincides with continued progress of the Company's Anticalin(R) development programs towards the clinic. PRS-050, Pieris' most advanced program addressing the modulation of VEGF for the treatment of cancer, is currently being prepared for...
Source: Genetics & Environmental Business Week (2007-11-22)
|
